Medigen Biotechnology Corp. focuses on the development of therapies for liver diseases and cancers in Taiwan. More Details
No risks detected for 3176 from our risk checks.
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Medigen Biotechnology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3176 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 3176's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 3176 underperformed the TW Biotechs industry which returned 22.8% over the past year.
Return vs Market: 3176 underperformed the TW Market which returned 31.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Medigen Biotechnology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StDoes Medigen Biotechnology (GTSM:3176) Have A Healthy Balance Sheet?
2 months ago | Simply Wall StShould Medigen Biotechnology (GTSM:3176) Be Disappointed With Their 49% Profit?
4 months ago | Simply Wall StIs Medigen Biotechnology (GTSM:3176) A Risky Investment?
Is Medigen Biotechnology undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 3176's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 3176's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 3176 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.
PE vs Market: 3176 is unprofitable, so we can't compare its PE Ratio to the TW market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 3176's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 3176's PB Ratio (4.8x) is in line with the TW Biotechs industry average.
How is Medigen Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medigen Biotechnology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Medigen Biotechnology's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Medigen Biotechnology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3176 is currently unprofitable.
Growing Profit Margin: 3176 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 3176 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.6% per year.
Accelerating Growth: Unable to compare 3176's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 3176 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).
Return on Equity
High ROE: 3176 has a negative Return on Equity (-37.05%), as it is currently unprofitable.
How is Medigen Biotechnology's financial position?
Financial Position Analysis
Short Term Liabilities: 3176's short term assets (NT$1.5B) exceed its short term liabilities (NT$976.6M).
Long Term Liabilities: 3176's short term assets (NT$1.5B) exceed its long term liabilities (NT$1.2B).
Debt to Equity History and Analysis
Debt Level: 3176's debt to equity ratio (50.5%) is considered high.
Reducing Debt: 3176's debt to equity ratio has increased from 26.9% to 50.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 3176 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 3176 has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 7% each year.
What is Medigen Biotechnology current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 3176's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 3176's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 3176's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 3176's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 3176's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
How experienced are the management team and are they aligned to shareholders interests?
Stanley Chang (61 yo)
Dr. Shi-Chung Chang, also known as Stanley, MD, Ph.D., serves as the Chairman and Chief Executive Officer of Medigen Biotechnology Corporation. Dr. Chang is a Urological surgeon by training, and was former...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Medigen Biotechnology Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Medigen Biotechnology Corp.
- Ticker: 3176
- Exchange: GTSM
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$6.949b
- Shares outstanding: 138.99m
- Website: https://www.medigen.com.tw
- Medigen Biotechnology Corp.
- No.3, Park Street
- 14th Floor
- Taipei City
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|3176||GTSM (Taipei Exchange)||Yes||Common Stock||TW||TWD||Dec 2003|
Medigen Biotechnology Corp. focuses on the development of therapies for liver diseases and cancers in Taiwan. The company offers PI-88 (MUPAFOSTAT) that is in Phase III clinical trial for the treatment of ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/23 08:49|
|End of Day Share Price||2021/01/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.